MassMutual Private Wealth & Trust FSB Purchases 1,384 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• MassMutual Private Wealth & Trust FSB increased its stake in Thermo Fisher Scientific Inc. by 2.7% during the second quarter, bringing its total holdings to 53,144 shares valued at approximately $21.55 million.
• A significant number of institutional investors, including Vanguard Group and UBS AM, recently raised their stakes in Thermo Fisher, which now sees 89.23% of its stock owned by institutional investors.
• Thermo Fisher Scientific reported a quarterly EPS of $5.36, surpassing analyst expectations, with a revenue of $10.86 billion, reflecting a 2.9% year-over-year growth.

MassMutual Private Wealth & Trust FSB grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 53,144 shares of the medical research company's stock after acquiring an additional 1,384 shares during the period. MassMutual Private Wealth & Trust FSB's holdings in Thermo Fisher Scientific were worth $21,548,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after acquiring an additional 230,382 shares during the last quarter. Amundi raised its stake in shares of Thermo Fisher Scientific by 5.9% in the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after acquiring an additional 168,197 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Thermo Fisher Scientific by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after acquiring an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after buying an additional 193,378 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after buying an additional 329,974 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 over the last ninety days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $474.73 on Tuesday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm's fifty day moving average price is $467.98 and its two-hundred day moving average price is $450.20. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $623.77. The firm has a market capitalization of $179.26 billion, a P/E ratio of 27.46, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the firm posted $5.37 earnings per share. The company's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Analysts Set New Price Targets

A number of research firms recently weighed in on TMO. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research note on Friday, July 11th. HSBC reissued a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Finally, William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating for the company. Seventeen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $592.24.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.